Health Equity and Access to Medicines
Increasing access to quality medicines is essential to improving people’s health - especially for the millions of patients who continue to face barriers to care.
According to the WHO, around one-third of the world’s population lacks reliable access to medicines, vaccines, diagnostic tools and other essential treatments and underserved populations are often unable to afford or obtain the care they need.
We want to help close that gap. Guided by global health priorities, we focus on practical, scalable approaches that maximize impact through:
Our broad portfolio of quality medicines includes innovative products that help address unmet health needs, while our generic and biosimilar medicines offer more affordable options and reach patients across the globe.
We currently have eight Access to Medicines Programs that address critical unmet health needs in populations with limited access to healthcare. Working with trusted partners who understand local communities and health systems, we implement product donations through tailored, country-specific models to ensure our medicines reach patients who would otherwise go without treatment.
In addition to our strategic Access to Medicines programs, Teva markets across the globe execute product donations consistently in order to increase access. We have donated approximately 2 billion units globally between 2021 and 2025, representing an estimated value of $3.5 billion. In 2025 alone we reached ~8 million patients through our global product donations. This impact underscores our role in addressing healthcare gaps and helping patients access essential medicines.
Bridging healthcare gaps means more than providing medicines -
it requires strong local health systems.
In order to achieve lasting impact, we have expanded a number of our access programs to go beyond the product by incorporating Health System Strengthening and Capacity Building efforts to improve care quality and accessibility. Through these initiatives, we expand healthcare professionals’ skills, enhance diagnosis and treatment pathways, strengthen community health literacy, and improve local infrastructure.
In 2025 alone, we reached ~400,000 people through our health systems strengthening activities.
We’re committed to building resilient systems that deliver better care today and sustain it for the future.
When disasters strike, access to essential medicines can be life-saving, yet difficult to deliver with the speed needed. We have developed key strategic partnerships and a trusted network to deliver critical treatments quickly to where they’re needed most.
During Hurricanes Melissa and the California wildfires, Teva donated over 9 million doses for conditions like diabetes, cardiovascular disease, and infections. To strengthen preparedness, we launched the Strategic Emergency Stockpile (SES) with Direct Relief - maintaining reserves of essential medicines for immediate deployment worldwide. These efforts enhance resilience and ensure patients receive timely care during crises.
Increasing Regulatory Submissions in Low- and Middle-Income Countries
Health equity and access to medicines depend on ensuring that essential treatments are available - and that begins with regulatory approval.
We are working to bring more medicines to low- and middle-income countries (LMICs), particularly for noncommunicable diseases (NCDs), by increasing regulatory submissions across six key therapeutic areas aligned with the WHO Essential Medicines List.
Advancing Patient Centricity in Clinical Development
Putting patients at the heart of clinical research ensures our medicines meet real needs and improve outcomes.
We’re making trials more accessible and inclusive through:
- Patient and Caregiver Engagement to help shaping clinical trial design
- Inclusivity in Clinical Trials, enrolling participants from a wide range
of backgrounds - Decentralized Clinical Trials to include home visits and remote technologies
- Communication and Site Awareness through working closely with
clinical trial sites
Our Access to Medicines - 8 Programs:
1. Global HOPE (Hematology-Oncology Pediatric Excellence)
Donations
Malawi, Uganda, Botswana, Tanzania and Rwanda
Sub-Saharan Africa faces a childhood cancer crisis due to a lack of pediatric cancer care.
We support Global HOPE, providing medicines for children with cancer and blood disorders in the region. Additionally, Pediatric oncology specialists are few and far between in Sub-Saharan Africa.
We expanded our support for Global HOPE in 2024 through efforts specifically focused on strengthening local capacity, including training for nurses and medical officers, as well as nurse training scholarships.
We have also committed to providing point-of-care Sickle Cell Disease testing kits to remote populations with the commitment of screening over 60,000 children. In 2025 alone, we reached over 22,000 children with our medicines and ~1,500 beneficiaries through our training and diagnosis activities.
2. Breast Cancer awareness and treatment in Ghana
Donations
Ghana
In Ghana, breast cancer is the most common cancer among women, and patients often lack access to healthcare systems and medicines.
Through our long-term partnership with Breast Care International, we donated more than 385,000 doses of medicine in 2025 worth ~$3.3 million, reaching ~1,000 patients with breast cancer.
In addition, we are addressing healthcare challenges that hinder early diagnosis and treatment, ensuring that patients receive the care they need. We are raising awareness on breast cancer and the importance of early diagnosis, increasing local capacity to increase breast cancer screening for women aged 18–60, and improving referral pathways. In 2025 alone we reached over 33,000 beneficiaries through these activities.
3. Community Routes, Access to mental health care in the US
Donations
USA
The "Community Routes: Access to Mental Health Care" program is a U.S. initiative in partnership with Direct Relief and the National Association of Free & Charitable Clinics (NAFC), providing donated depression and anxiety medications and grant funding to free clinics for uninsured, underserved populations, aiming to remove barriers to mental health care and improve health equity.
In early 2025, Teva made an additional commitment of $2 million over two years and announced a new cohort of 11 grantees across Alabama, Mississippi and Texas to support behavioral health services.
In 2025 alone, we donated over 6.2 million doses, reaching almost 25,000 patients with our medicines. Additionally, we have reached over 57,000 beneficiaries through our health equity initiatives.
4. Strategic Emergency Stockpile (SES)
Donations
The SES program supports the Strategic Emergency Stockpile, an initiative managed by Direct Relief. It ensures that essential medical supplies are readily available for rapid deployment in crisis situations, thereby enhancing the resilience and responsiveness of healthcare systems worldwide.
By maintaining a strategic reserve of vital medications, Teva and Direct Relief can promptly react to address health emergencies, mitigate the impact of disasters and support affected communities.
In 2025 alone, we donated over 8.5 million doses, reaching ~84,500 people.
5. Supporting underserved communities in El Salvador
Donations
El Salvador
People with low income in El Salvador have little or no access to basic healthcare services, while the burden of non-communicable diseases (NCDs) continues to grow.
In 2024 we partnered with Americares and FUSAL to launch a program enhancing access to medicines for vulnerable populations in El Salvador.
The program is active in clinics in two cities and focuses on NCDs such as cardiovascular and respiratory conditions, diabetes and pain management.
In 2025, we donated over 180,000 doses, reaching ~3,800 patients through this program.
6. Friends for health in Israel
Donations
Israel
Patients in need in Israel often struggle to access essential treatments due to socioeconomic hardship or the high cost of medications not covered by the national health insurance system or private insurers.
As a result, individuals cannot obtain the life-saving therapies they require. To help close this gap, we collaborate with Friends for Health (Haverim L’Refuah), a local NGO that collects medications and receives donated products to support underserved patients. Through this program, we donated over 500,000 doses in 2025, reaching over 5,000 patients.
7. Supporting underserved communities in Spain
Social Business
Spain
Approximately 1.5 million people in Spain cannot afford prescription medicines and health products for chronic diseases.
We support Banco Farmacéutico to increase access to underserved populations, reaching almost 1,500 patients in 2025 with over 57,000 doses.
8. Supporting underserved communities in France
Social Business
France
In collaboration with Pharmacie Humanitaire Internationale, we supply medicine to charitable care centers that give medication, consultations and social services to underserved patients.
Through this program, we reached over 60,000 patients in 2025 with over 2 million doses.
Progress in Target
| Targets | Progress | Status |
|---|---|---|
| Increase the cumulative number of new regulatory submissions in low- and middle-income countries (LMICs) on the WHO Essential Medicines List (EML) across six key therapeutic areas (TAs)1 by 150% from 2022-2025 (vs. 2017-2020) 01 | 83 submissions cumulative (increased by 177% vs. 2017-2020) | Surpassed |
| New target: Increase the cumulative number of new regulatory submissions in low- and middle-income countries (LMICs) on the WHO Essential Medicines List (EML) across six key therapeutic areas (TAs)1 by 220% from 2022–2027 (vs. 2017–2020) 01 | 83 submissions cumulative (increased by 177% vs. 2017-2020) | On track |
| Increase access to medicines program product volume by 150% in 2025 (vs. 2020) through four access to medicines programs, including donations and social business in LMICs on WHO’s EML across six key TAs 01 02 | 6.7m single unit doses provided (increased by 1242% vs. 2020) | Surpassed |
| New target: Increase the cumulative number of underserved patients reached with product through Access initiatives to at least 1 million from 2023 to 2029 | 537,836 patients reached with our medicines (54% of our target) | On track |
| Increase the cumulative number of beneficiaries of health system-strengthening and capacity-building initiatives in support of underserved populations by 200% by 2026 (vs. cumulative 2022-2023 baseline) | 499,809 beneficiaries reached (~1700% of target) | Surpassed |
| Incorporate a patient-centric approach in 100% of clinical trials for innovative products by 2030, which will help enable more equitable access to medicines | 100% of clinical trials for innovative products initiated in 2025 incorporated a patient centric approach | On track |
Footnotes
-
Back to contents.
Target is part of sustainability-linked bond.
-
Back to contents.
Therapeutic areas for submissions include: cardiovascular diseases, pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care. Therapeutic areas for volumes include: cardiovascular diseases, adult and pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care.